Behavior and Learning Study for 6 to 21 Year Olds with Tuberous
Sclerosis Complex (TSC) What is the purpose of this study?
Children’s is conducting a research study, sometimes known as a
clinical trial or clinical study, to determine if the study
medication, RAD001 or Everolimus, can help improve how well
people with TSC think, learn and behave as well as confirm the
safety of this study medication. approved by the Food and Drug
Administration (FDA) for the treatment of individuals of all
ages with subependymal giant cell astrocytoma’s (SEGA) and
adults with acute myelogenous leukemia (AML). Who can
participate? Children and adults diagnosed with TSC who: - Are 6
to 21 years old an IQ of 60 or higher been on the same seizure
medication(s), if applicable, for at least 6 months What is
involved? or your child will be in the research study for about
7 months and have 9 study visits and 3 phone visits.
Participants will be randomly chosen to receive either the study
medication (RAD001) or a placebo (a substance t